#	Pagina
attuale pagina	/open-h2020/projects/209452/index.html

Opendata, web and dolomites

EBOVAC1 SIGNED

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

EBOVAC1 project word cloud

Explore the words cloud of the EBOVAC1 project. It provides you a very rough idea of what is the project "EBOVAC1" about.

elicited ebovac2 enrolled boost compressed evd december consequently urgent raised africa health proposals ad26 schedule translational filo bnfilo initial zebov separate imi2 expedite vaccinated immunogenic primates bn link epidemic unaffected 300 100 human parts countries 2015 safety time protection prime march ordinated ebola teams regimen co extensive 500 administering initiation trials ebovac1 public whereas mva efficacy 2014 uk immune immunogenicity approximately humans phase subjects parallel vaccine responding african intervals preclinical data nature prophylactic enrolment ebovac maximize heterologous disease split virus volunteers wp4 sequences

Project "EBOVAC1" data sheet

The following table provides information about the project.

Coordinator	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER Organization address address: KEPPEL STREET city: LONDON postcode: WC1E 7HT website: http://www.lshtm.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	http://www.ebovac.org
Total cost	98˙044˙689 €
EC max contribution	58˙336˙885 € (60%)
Programme	1. H2020-EU.3.1.7.13. (Other)
Code Call	H2020-JTI-IMI2-2014-02-single-stage
Funding Scheme	IMI2-RIA
Starting year	2014
Duration (year-month-day)	from 2014-12-01 to 2021-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER Organization address address: KEPPEL STREET city: LONDON postcode: WC1E 7HT website: http://www.lshtm.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	coordinator	44˙720˙692.00
2	UNIVERSITY OF SIERRA LEONE UNIVERSITY OF SIERRA LEONE Organization address address: COLLEGE OF MEDECINE & ALLIED HEALTH SCIENCES UNIVERSITY OF SIERRA LEONE NEW ENGLAND city: FREETOWN postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SL (FREETOWN)	participant	11˙524˙564.00
3	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	1˙437˙905.00
4	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	653˙722.00
5	JANSSEN VACCINES & PREVENTION BV JANSSEN VACCINES & PREVENTION BV Organization address address: ARCHIMEDESWEG 4 city: LEIDEN postcode: 2333 CN website: www.crucell.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	0.00

Map

Project objective

The overall aim of the EBOVAC programme is to assess the safety and efficacy of a novel prime boost prophylactic vaccine regimen against Ebola Virus Disease (EVD), which has been 100% effective in preclinical studies. This will be done via phase I, II and III trials carried out in the EU and in Africa, in response to the urgent public health need raised by the current Ebola epidemic. To expedite the development of the vaccine regimen, Phase II and Phase III trials will be carried out in parallel and therefore co-ordinated by two separate teams. Proposals responding to IMI2 Topic 1 will consequently be split into two parts. EBOVAC1 will address the Phase I and Phase III trials, whereas EBOVAC2 will address the Phase II trials.

EBOVAC1 will establish the initial safety and immunogenicity of the proposed heterologous prime/ boost regimen of Ad26.ZEBOV and MVA-BNFilo vaccine through phase I studies conducted in the UK, the US and currently Ebola- unaffected African countries. This will be done by administering the vaccine in different sequences and at different time intervals so as to identify the shortest schedule that is immunogenic and to maximize the potential for short term efficacy in affected countries. Initiation of these trials is expected to occur between December 2014 and March 2015 and approximately 300 subjects will be enrolled.

The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine.

This will be done by:

1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates (via WP4) 2. Carrying out Phase II trials in African and European volunteers in 6 countries, four in Africa and two in the EU with an overall target enrolment of approximately 1,500 subjects. Given the compressed nature of this development program, the Phase II studies will be conducted in parallel

Deliverables

List of deliverables.
Publish Information Governance Policy	Documents, reports	2019-04-02 13:36:04

Take a look to the deliverables list in detail: detailed list of EBOVAC1 deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	ChloÃ© Pasin, Irene Balelli, Thierry Van Effelterre, Viki Bockstal, Laura Solforosi, MÃ©lanie Prague, Macaya Douoguih, Rodolphe ThiÃ©baut Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation published pages: , ISSN: 0022-538X, DOI: 10.1128/jvi.00579-19	Journal of Virology 93/18	2020-03-05
2019	Mario Jendrossek, W. John Edmunds, Hana Rohan, Samuel Clifford, Thomas A. Mooney, Rosalind M. Eggo Health care worker vaccination against Ebola: Vaccine acceptance and employment duration in Sierra Leone published pages: 1101-1108, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2018.12.060	Vaccine 37/8	2020-03-05
2019	Alexis Robert, W John Edmunds, Conall H Watson, Ana Maria Henao-Restrepo, Pierre-StÃ©phane Gsell, Elizabeth Williamson, Ira M Longini, KeÃ¯ta Sakoba, Adam J Kucharski, Alhassane TourÃ©, SÃ©vÃ©rine Danmadji Nadlaou, Boubacar Diallo, Mamamdou Saidou Barry, Thierno Oumar Fofana, Louceny Camara, Ibrahima Lansana Kaba, Lansana Sylla, Mohamed Lamine Diaby, Ousmane Soumah, Abdourahime Diallo, Amadou Niar Determinants of Transmission Risk During the Late Stage of the West African Ebola Epidemic published pages: 1319-1327, ISSN: 0002-9262, DOI: 10.1093/aje/kwz090	American Journal of Epidemiology 188/7	2020-03-05
2019	Zacchaeus Anywaine, Hilary Whitworth, Pontiano Kaleebu, George Praygod, Georgi Shukarev, Daniela Manno, Saidi Kapiga, Heiner Grosskurth, Samuel Kalluvya, Viki Bockstal, Dickson Anumendem, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih, Deborah Watson-Jones Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania published pages: 46-56, ISSN: 0022-1899, DOI: 10.1093/infdis/jiz070	The Journal of Infectious Diseases 220/1	2020-03-05
2019	Alexis Robert, Anton Camacho, W. John Edmunds, Marc Baguelin, Jean-Jacques Muyembe Tamfum, Alicia Rosello, Sakoba KÃ©Ã¯ta, Rosalind M. Eggo Control of Ebola virus disease outbreaks: Comparison of health care worker-targeted and community vaccination strategies published pages: 106-114, ISSN: 1755-4365, DOI: 10.1016/j.epidem.2019.03.001	Epidemics 27	2020-03-05
2019	Gaudensia Mutua, Omu Anzala, Kerstin Luhn, Cynthia Robinson, Viki Bockstal, Dickson Anumendem, Macaya Douoguih Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya published pages: 57-67, ISSN: 0022-1899, DOI: 10.1093/infdis/jiz071	The Journal of Infectious Diseases 220/1	2020-03-05
2015	Anton Camacho, Rosalind M Eggo, Sebastian Funk, Conall H Watson, Adam J Kucharski, W John Edmunds Estimating the probability of demonstrating vaccine efficacy in the declining Ebola epidemic: a Bayesian modelling approach published pages: e009346, ISSN: 2044-6055, DOI: 10.1136/bmjopen-2015-009346	BMJ Open 5/12	2019-05-15
2016	An Vandebosch, Robin Mogg, Nele Goeyvaerts, Carla Truyers, Brian Greenwood, Debby Watson-Jones, Guillermo Herrera-Taracena, Wim Parys, Tony Vangeneugden Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges published pages: 57-65, ISSN: 1740-7745, DOI: 10.1177/1740774515621059	Clinical Trials: Journal of the Society for Clinical Trials 13/1	2019-05-15
2015	Rosalind M Eggo, Conall H Watson, Anton Camacho, Adam J Kucharski, Sebastian Funk, W John Edmunds Duration of Ebola virus RNA persistence in semen of survivors: population-level estimates and projections published pages: Volume 20, 2015, ISSN: 1025-496X, DOI: 10.2807/1560-7917.ES.2015.20.48.30083	Eurosurveillance 20/48	2019-05-15
2016	Adam J. Kucharski, Rosalind M. Eggo, Conall H. Watson, Anton Camacho, Sebastian Funk, W. John Edmunds Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease published pages: 105-108, ISSN: 1080-6040, DOI: 10.3201/eid2201.151410	Emerging Infectious Diseases 22/1	2019-05-15
2017	Rebecca L. Winslow, Iain D. Milligan, Merryn Voysey, Kerstin Luhn, Georgi Shukarev, Macaya Douoguih, Matthew D. Snape Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankaraâ€“Vectored Ebola Vaccines at 1 Year published pages: 1075, ISSN: 0098-7484, DOI: 10.1001/jama.2016.20644	JAMA 317/10	2019-05-15
2018	Martinus A.H. Capelle, Lara Babich, J.P. Els van Deventer-Troost, Doris Salerno, Kelly Krijgsman, Ulrike Dirmeier, Britt Raaby, Janik Adriaansen Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BNÂ®-Filo heterologous prime-boost Ebola vaccine published pages: 215-221, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2018.06.001	European Journal of Pharmaceutics and Biopharmaceutics 129	2019-04-18
2018	Luisa Enria, Shelley Lees Citizens, dependents, sons of the soil: Defining political subjectivities through encounters with biomedicine during the Ebola epidemic in Sierra Leone published pages: , ISSN: 2405-691X, DOI: 10.17157/mat.5.4.512	Medicine Anthropology Theory \| An open-access journal in the anthropology of health, illness, and medicine 5/4	2019-04-18
2018	Angus Fayia Tengbeh, Luisa Enria, Elizabeth Smout, Thomas Mooney, Mike Callaghan, David Ishola, Bailah Leigh, Deborah Watson-Jones, Brian Greenwood, Heidi Larson, Shelley Lees â€œWe are the heroes because we are ready to die for this countryâ€: Participants\' decision-making and grounded ethics in an Ebola vaccine clinical trial published pages: 35-42, ISSN: 0277-9536, DOI: 10.1016/j.socscimed.2018.03.008	Social Science & Medicine 203	2019-04-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOVAC1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EBOVAC1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.13.)

EBOVAC1 (2014)

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854

VSV-EBOVAC (2015)

Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

ADAPT-SMART (2015)

Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890